We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Puja P. Khanna, MD, MPH, of the University of Michigan, ...

A drug currently used to prevent rejection in patients who receive solid organ transplants could have a use in the treatment of a completely different patient population ― those with immune ...

Credit: Azurity Pharmaceuticals. Myhibbin is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection. Myhibbin is expected to be commercially available in the second ...

Please provide your email address to receive an email when new articles are posted on . Adding mycophenolate mofetil to a glucocorticoid in first-line treatment for immune thrombocytopenia improves ...

Early use of mycophenolate mofetil in at-risk patients with SLE reduced the risk of severe flare, potentially delaying lupus nephritis. Early application of mycophenolate mofetil may reduce the ...

† One patient had MMF as an initial treatment. ‡ In the study TAC and MMF were used alone or in combination. §In total, 17 patients were initially treated with MMF and steroids. ¶ Females represented ...

The addition of mycophenolate mofetil (MMF) to a glucocorticoid as a first-line treatment for immune thrombocytopenia (ITP) resulted in greater responses and a reduced risk of relapse or refractory ...

In a new analysis of the BLISS LN trial, researchers added Belimumab (Benlysta) to Mycophenolate (MMF), the standard of care treatment for lupus nephritis, (LN, lupus-related kidney disease) and found ...

Acute GVHD (aGVHD) remains a matter of concern after reduced intensity conditioning (RIC) allo-SCT, and its incidence might be expected to be higher when using allogeneic grafts from HLA-matched ...